Last reviewed · How we verify
Td-IPV
At a glance
| Generic name | Td-IPV |
|---|---|
| Sponsor | Dimitri Diavatopoulos |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy (PHASE1)
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- A Phase 4, Randomised Vaccination Study in Healthy Adults to Investigate the Effects of Acellular Pertussis Vaccine on Colonisation with Bordetella Pertussis Using Controlled Human Infection (PHASE4)
- National Vaccine Adverse Event Reporting Survey and Etiology
- Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) (PHASE4)
- Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Td-IPV CI brief — competitive landscape report
- Td-IPV updates RSS · CI watch RSS
- Dimitri Diavatopoulos portfolio CI